Introduction {#S1}
============

Despite modern multidrug therapy [@R1] and ongoing drug development [@R2],[@R3], tuberculosis (TB) continues to be a major health concern with nine million new cases and two million deaths worldwide in 2007 alone [@R4], which makes the emergence of strains of *Mycobacterium tuberculosis,* the causative agent of TB, that are resistant to the most widely used antibiotics a significant health problem. Among the most effective antibiotics against multidrug-resistant TB are the tuberactinomycins. The tuberactinomycins inhibit protein synthesis by interacting with both ribosomal subunits in a manner that was unknown until the present study [@R5].

The tuberactinomycin family of antibiotics consists of several closely related compounds containing the same pentapeptide core that is composed of L-serine and the nonproteinogenic amino acids 2,3-diaminopropionate, L-capreomycidine, and β-ureidodehydroalanine ([Fig. 1](#F1){ref-type="fig"}). The members of the tuberactinomycin family differ in their amino acid side chain modifications, including the amino acylation with β-lysine [@R6]. Although viomycin was the first member of this family to be identified, only capreomycin is commonly used clinically as a second-line antibiotic against infections by *Mycobacterium tuberculosis* [@R7]. Capreomycin is a mixture of four isoforms, all of which are active *in vitro* against mycobacteria [@R8]. To simplify the discussion here, only the IA isoform of capreomycin is considered ([Fig. 1](#F1){ref-type="fig"}); other isoforms either are not modified with β-lysine and/or have the serine of the cyclic pentapeptide core reduced to alanine ([Supplementary Fig.1](#SD1){ref-type="supplementary-material"}).

In addition to its important role in the treatment of TB, viomycin has played a pivotal role in biochemical studies of protein synthesis. Viomycin interacts with both the large and the small ribosomal subunits [@R5] and prevents the translocation of the ribosome along the mRNA [@R9]. During translocation, a deacylated tRNA moves from the P site to the E site and the peptidyl-tRNA moves from the A site to the P site to vacate the A site for the next aminoacylated tRNA. Elongation Factor G (EF-G) facilitates translocation using GTP hydrolysis. Although, viomycin allows the binding of EF-G and GTP hydrolysis, it completely inhibits translocation [@R9]. To confirm the proposed binding site and illuminate the mechanism of translocation inhibition we set out to determine the structure of both capreomycin and viomycin bound to the ribosome.

Results {#S2}
=======

The co-crystal structures of the 70S ribosome from *Thermus thermophilus* complexed with either viomycin or capreomycin as well as three full length tRNAs and a short piece of mRNA were determined at 3.3 and 3.5 Å resolution, respectively. Both antibiotics were bound to *T. thermophilus* 70S ribosomes that had been complexed with mRNA and tRNA prior to crystallization. The preparation of ribosomes containing the 3 bound tRNAs required the incubation with the ternary complex of EF-Tu, GMP-PNP and Gln-tRNA^Gln^ (see methods). Unbiased difference Fourier maps were calculated using the observed amplitudes from crystals of the complex and the amplitudes and phases that were calculated using a model of the 70S ribosome without the bound ligands obtained by molecular replacement. Each antibiotic as well as the tRNA and mRNA could be manually fit into the difference electron density map ([Fig. 1c](#F1){ref-type="fig"}), and the coordinates of the entire ribosome complex with the antibiotic, tRNAs and mRNA were then refined. The distinctive axial conformation of the six membered ring of the L-capreomycidine side chain allowed the central tuberactinomycin ring to be unambiguously placed into the difference Fourier maps, despite the presence of the four isoforms of capreomycin.

The three tRNA molecules are bound in the classical A, P and E sites in this complex with the 70S ribosome. The anticodons of both the A-site and the P-site tRNAs form base-pairs with the corresponding codons of the mRNA. As observed earlier [@R10], the bases A1492 and A1493 make stabilizing A-minor interactions with the two base-pairs between the codon and anti-codon of the A-site tRNA and mRNA. The structure of peptidyl transferase center and the bound CCA ends of both the A-site and P-site tRNAs is identical to that of the *Haloarcula marismortui* large subunit complexed with A- and P-site substrate analogues [@R11], consistent with the recent results of Ramakrishnan and colleagues [@R12] ([Supplementary Fig. 2](#SD1){ref-type="supplementary-material"}).

Both viomycin and capreomycin bind to a site that lies between the large and small subunit in a cleft formed between helix 44 of the 16S rRNA (h44) and the tip of Helix 69 of 23S rRNA (H69)([Fig. 2](#F2){ref-type="fig"}). The macrocycle of both drugs lies within hydrogen bonding distance of the ribose-phosphate backbone of the binding pocket, which is formed by residues A1913 and C1914 of the 23S rRNA and residues A1493 and G1494 of the 16S rRNA. This explains why cleavage of the phosphate backbone between A1493 and G1494, produced by colicin E3, renders the ribosome less sensitive to inhibition by viomycin [@R13]. The orientation of the macrocycle is also determined by its stacking onto the base of G1491 and G1494, which places the six membered ring of the capreomycidine side chain in the vicinity of the bases of A1492 and A1493 of the 16S rRNA. The guanidinium moiety in the six membered ring of capreomycidine effectively positions the antibiotic by making a salt bridge to the phosphate of A1493 of the 16S rRNA ([Fig. 2c](#F2){ref-type="fig"}). Previous biochemical work has established the importance of the capreomycidine side chain of the tuberactinomycins ring for its inhibition of the ribosome activity, suggesting that its steric restriction of the orientation of A1492 and A1493 contributes to the inhibitory effect of viomycin and capreomycin [@R14]; A1492 and A1493 cannot move to the positions they occupy in the *apo*-ribosome in the presence of these antibiotics.

The main difference between the binding of viomycin and capreomycin to the 70S ribosome is in the β-lysine side chain of each drug. Because only 2 of the 4 isoforms of capreomycin possess the β-lysine modification, the electron density observed for β-lysine in the complex between capreomycin and the ribosome is weak. The β-lysine side chain in the capreomycin complex extends from the macrocycle, past A1913 of the 23S rRNA and towards the A-site tRNA, while in the viomycin complex it extents past G1491 of the 16S rRNA towards the mRNA. Neither position of the β-lysine modification is essential for the activity of the antibiotic [@R15],[@R16], which is confirmed by the lack of extensive hydrogen bonding between the ribosome and the modification.

Discussion {#S3}
==========

The structures of both viomycin and capreomycin bound to the ribosome confirm a wealth of previous biochemical and genetic studies which suggested that the tuberactinomycins bind at the interface between the small and large ribosomal subunits. Both tuberactinomycins bind to the well conserved intersubunit bridge B2a formed by the interactions of H69 of the 23S rRNA and h44 of the 16S rRNA. Mutations of nucleotides in both H69 and h44 that surround the antibiotic binding site, confer resistance to capreomycin and viomycin [@R17]. The loss of 2' methylation of C1409 of h44 and C1920 of H69 reduces the susceptibility of *Mycobacterium tuberculosis* to capreomycin and viomycin by two to eightfold [@R7] but has no effect on capreomycin sensitivity in *T. thermophilus* [@R17]. Of particular interest is the mutation A1913U, which was identified in *T. thermophilus* [@R17]. In the structure of the *apo* 70S ribosome the base of A1913 is swung out of the loop at the base of H69 and inserted into h44 [@R18], a position which partially overlaps with the binding site of both capreomycin and viomycin. The mutation of A1913 to U may confer resistance to these antibiotics because this potential clash between A1913 and the antibiotic could be alleviated, which also suggests that bound tuberactinomycins inhibit translocation by preventing A1913 from moving into the position it occupies in the structure of the *apo* 70S-ribosome.

The bridge between the subunits formed by H69 and h44 is not only essential for the association of ribosomal subunits in the absence of tRNA [@R19], but also contacts the A-site tRNA implying that it has roles in several ribosomal functions such as initiation, decoding, or ribosome recycling [@R20]--[@R22]. Several different orientations of this bridge have been observed in the crystal structures of ribosome complexes with tRNAs, release factors and antibiotics [@R18],[@R22]--[@R28]. The positions of A1913 of the 23S rRNA as well as A1492 and A1493 of the 16S rRNA play a critical role in the decoding of the mRNA. The positions of A1492, A1493, and A1913 in the structures presented here are identical to those observed with complexes containing mRNA and cognate tRNA in the A site [@R10],[@R24]. During the binding of the cognate A-site tRNA, the nucleotides A1492 and A1493 swing out of h44 and, along with G530 of the 16S rRNA, form A minor interactions with the helix that is formed by the codon:anticodon interactions between the cognate tRNA and the mRNA [@R10]. In addition, A1913 rotates towards the A-site tRNA to hydrogen bond with the 2'-OH of nucleotide 37 of the A-site tRNA [@R24].

Chemical modification experiments [@R29] and cryo-EM structures [@R30] show that the tRNAs can assume a hybrid state, in which the tRNAs bound in the A site and P site adopt the A/P and P/E hybrid states, respectively, after the peptidyl transfer reaction. There are reports on the effects of viomycin on these hybrid states, which are not in agreement with each other. These disagreements might just be the consequence of the differing ionic conditions used on these experiments, which could influence the sensitive equilibrium between the two states [@R30],[@R31]. Single molecule-FRET experiments suggest that viomycin not only stabilizes the classical state, but also suppresses the rate of sampling the hybrid state by the tRNAs after peptide bond formation [@R31]. Other kinetic data suggest that the binding of viomycin to the 70S ribosome after the addition of EF-G and GTP blocks only the movement of the A-site tRNA but not the formation of the hybrid state by the P-site tRNA [@R32]. Chemical modification experiments seem to indicate that viomycin traps the tRNAs in the A/P and P/E hybrid state [@R33]. Single molecule FRET experiments [@R34] have correlated both the tRNA hybrid state and the viomycin stalled state with the ratcheted state of the ribosome, in which the large subunit is rotated relative to the small and tRNAs. While we cannot confirm or refute the possibility that these antibiotics bind to the 70S ribosome in the hybrid state, our results show that they can bind to the classical state.

In both structures of the ribosome in complex with viomycin and capreomycin, the ribosome is observed in the non-ratcheted with the bound tRNAs in the classical A, P and E sites rather than in the ratcheted state with the bound tRNA in the hybrid state. Crystal packing and/or the presence of an E-site tRNA in these crystals may prevent the formation of the hybrid state. Although, these structures demonstrate that viomycin is able to bind to the ribosome when the A-site tRNA is in the classical state, we cannot exclude the possibility that viomycin is capable of binding to the ratcheted state as well. Cryo-EM structures have revealed that bridge B2a, which is consists of h44 and H69, remains intact after spontaneous ratcheting of the subunits, however slight movements of h44 and H69 were observed [@R30]. This is further supported by recent crystals structures of the 70S ribosome from *E. coli* captured in intermediate states of ratcheting, which show that the contacts in B2a persist in the different proposed intermediate states [@R35]. Whether or not the binding of viomycin inhibits the movement of B2a that is associated with ratcheting is unknown.

The many different classes of antibiotics that affect translocation of the tRNAs on the ribosome, such as the tuberactinomycins or aminoglycosides (Reviewed in [@R36]) either stabilize the tRNA in the pre-translocation state or interfere with the conformational changes of the ribosome or tRNA required for translocation [@R37]. Paromomycin is an aminoglycoside that binds into the major groove of h44 and stabilizes A1492 and A1493 of the 16S rRNA in the flipped out position that the bases adopt during the readout interaction between the tRNA anticodon and the mRNA [@R10]. Because paromomycin stabilizes the binding of both cognate and near-cognate tRNAs to the A site, it not only inhibits translocation but also promotes miscoding [@R38]. Interestingly, although hygromycin B also binds to h44, it causes only the base of A1493 to adopt a unique orientation, in which the base interferes with the movement of the tRNA from the A site to the P site [@R39].

Viomycin and capreomycin not only affect the positioning of the bases of A1492 and A1493 ([Fig. 3](#F3){ref-type="fig"}), but they also appear to affect the position of A1913 of the 23S rRNA. The base of A1913 adopts a position where it forms hydrogen bonds with the A-site tRNA. Consistent with our results is the biochemical evidence that viomycin increases the affinity of tRNA to the A site by 1000 fold [@R37] and promotes the back translocation of the complex of tRNA with mRNA on the ribosome [@R40]. Therefore we propose that the tuberactinomycins inhibit translocation stabilizing the tRNA in the A-site.

We suggest that these two structures of tuberactinomycins in complex with the 70S ribosome will enable the creation of new anti-TB antibiotics. The tuberactinomycins have several functional groups that can be modified without decreasing the potency of their inhibition of translation making them particularly amenable for structural based drug design [@R16]. Furthermore, the adjacent location of the tuberactinomycin binding site with those of paromomycin and hygromycin should provide an enabling starting point for the design of novel derivatives of tuberactinomycins that are chemically linked to modified portions of the other antibiotics. These new compounds could be effective against drug resistant strains of TB, including those with mutant efflux pumps.

Methods {#S4}
=======

Purification of 70S ribosomes, mRNA, tRNA, and ternary complex {#S5}
--------------------------------------------------------------

*Thermus thermophilus* 70S ribosomes and fMet-tRNA were prepared as described previously [@R24],[@R41],[@R42]. The mRNA was chemically synthesized by Integrated DNA Technologies (Coraliville, IA) and contained a codon for Gln following the fMet start codon. The ternary complex of EF-Tu, Gln-tRNA^Gln^ and GMP-PNP was formed from purified components. The plasmids for the overexpression of His-tagged T.th. EF-Tu and His-tagged T.th. EF-Ts were provided by Poul Nissen and Mathias Sprinzl, respectively. Both EF-Tu and EF-Ts were expressed and purified following standard protocols. tRNA^Gln^ and Gln-RS were prepared as described previously [@R43]. Prior to ternary complex formation with Gln-tRNA^Gln^, the nucleotide bound to EF-Tu was exchanged to GMP-PNP. The final ternary complex was purified with a reverse ammonium sulfate gradient on a phenyl resource column (GE, Piscataway, NJ).

Formation of the 70S ribosome complex {#S6}
-------------------------------------

The complex of 70S ribosomes with viomycin (or capreomycin), mRNA and three tRNAs was formed in 5 mM Hepes- KOH (pH 7.6), 10 mM MgCl~2~, 50 mM KCl, 10 mM NH~4~Cl at 55°C. 4 µM of 70S ribosomes were programmed with 8 µM mRNA for 15 minutes, before incubating with 8 µM of fMet-tRNA~i~^Met^ for an additional 30 minutes. 16 µM of ternary complex was added to the reaction mixture and incubated for 30 minutes followed by the addition of either 100 µM of viomycin or 250 µM capreomycin and a final incubation of 30 minutes. The complex was cooled to room temperature and briefly centrifuged prior to setting up the crystallization experiment.

Crystallization {#S7}
---------------

Crystals were grown by vapor diffusion in hanging drop crystallization trays, in which 1--2 µL of the ribosome complex was mixed with 1--2 µL of the reservoir solution that contained: 0.1--0.2 M Arginine-HCl, 0.1 M Tris-HCl (pH 7.6), 2.5%(w/v) PEG 20K, 7--12%(v/v) MPD, 0.5 mM BME. Within 2--5 days crystals of 50 × 100 × 1000 µm in size appeared. The crystals were stabilized by slowly increasing the concentration of MDP to a final concentration of 30%(v/v) before flash freezing in liquid nitrogen.

Data Collection {#S8}
---------------

Xray diffraction data were collected at beamlines X29 at Brookhaven National Laboratory (Upton, NY) and 24ID at the Advanced Photon Source (Argone, IL). Complete datasets for both the viomycin and capreomycin crystals were collected from four separate regions of the same crystal. The raw data were integrated and scaled with the XDS package [@R44]. The crystals belong to the orthorhombic spacegroup P2~1~2~1~2~1~ with two copies of the ribosomal complex in the asymmetric unit.

Structure Determination {#S9}
-----------------------

Each structure was solved by molecular replacement using the small and large ribosomal subunits from the structure of the *T. th.* 70S ribosome bound to mRNA and tRNA (PDB ID's 2J00 and 2J01) using phaser in the CCP4 programming suite [@R45]. Neither the tRNAs nor the mRNA ligands were included in the search models. The initial molecular replacement structures were refined by rigid body refinement with the ribosome split into multiple domains using REFMAC in the CCP4 programming suite [@R46]. After rigid body refinement in REFMAC5 each structure was refined using Phenix, which enabled the calculation of difference electron density maps using Fo-Fc coefficients [@R47]. Clear difference electron densities were visible for 3 full length tRNAs, the mRNA, and both antibiotics, which were used for building the ligands.

Structure Building {#S10}
------------------

Iterative rounds of model building and refinement were carried out in Coot [@R48] and CNS [@R49],[@R50]. While the crystal structure of viomycin was reported in the literature [@R51] the coordinates are not available in the Cambridge Structural Database. The initial coordinates of viomycin and capreomycin were based on the combination of a model derived from the published crystal structure of tuberactinomycin [@R52], chemical structure information and energy minimization with the program Desmond [@R53]. Initial structures were energy minimized using OPLS-AA force field [@R54] and TIP4P water model [@R55] via steepest descent / L-BFGS, followed by 1.2 ps of five-stage simulated annealing (0, 300K, 600K, 900K, 300K), and another cycle of energy minimization. The starting coordinates for the tRNA and mRNA ligands were taken from (PDB ID 2WGK [@R12]). The deacylated non-cognate tRNA bound in the E-site was build with the same sequence as the A-site tRNA^Gln^. The statistics on the X-ray data and the refinement are available in [Table 1](#T1){ref-type="table"}. Figures were generated with PYMOL [@R56].
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![Chemical Structure of the tuberactinomycins. (**a**) The chemical structures of viomycin and capreomycin IA. For simplicity only capreomycin IA is displayed. The other isoforms of capreomycin contain fewer functional groups ([supplemental fig.1](#SD1){ref-type="supplementary-material"}). The distinctive features of viomycin are in magenta and those of capreomycin are in pink. (**b**) Chemical structures of the unusual amino acids, from which the tuberactinomycins are built and which are referred to in the text. (**c**) Unbaised Fo-Fc difference Fourier map for viomycin and capreomyicn bound to a complex of T. thermophilus 70S, mRNA and tRNAs. The difference electron densities are contoured at 2.8 and 3.0 σ for viomycin (left) and capreomycin (right), and the refined models of viomycin (magenta) and capreomyicn (pink) are superimposed.](nihms223159f1){#F1}

![Binding site of Viomycin and Capreomycin. (**a**) Overview of the entire structure of the ribosome complex with viomycin. Both the 50S ribosomal subunit (cyan) and the 30S ribosomal subunit (light brown) are shown in surface representation. The A-site tRNA (yellow) and the P-site tRNA (blue) are shown in ribbon, while viomycin (magenta) is shown as a spacefilled model. (**b**) Close up view of the viomycin binding site as shown in (a). The codon:anticodon base pairing between the A-site tRNA (yellow) and the mRNA (green) is indicated as black dashed lines. (**c**) Detailed view of the binding site of viomycin (magenta) illustrating its close proximity to A1492, A1493, and G1491 of h44 and A1913 and C1914 of H69. (**d**) Detailed view of the binding site of capreomycin (yellow) illustrating its close proximity to A1492, A1493, and G1491 of h44 and A1913 and G1941 of H69.](nihms223159f2){#F2}

![Overlapping Binding Sites. (**a**) The region around 1492 and 1493 of h44 showing their base stacking in the apo 70S ribosome of *E. coli* (PDB ID 2AW4) [@R18]. The nitrogens of the base of A1492 and A1493 are in blue and all other atoms are in light brown. (**b**) The binding site of hygromycin B showing the "flipped out" orientations of 1492 and 1493. The *carbons* of hygromycin are in green, the nitrogens in blue and the oxygens in red. The colour coding of the 16S rRNA is the same in (a). The coordinates were taken from PDB IDs 3DF1 [@R39]. (**c**) The binding site of paromomycin (yellow). The coordinates were taken from PDB ID 2WDG [@R12]. (**d**) The binding site of viomycin (magenta) showing the same "flipped out" orientation of 1492 and 1493 as in (c). (**e**) Overlap of the binding sites of hygromycin B, paromomycin and viomycin. The superpositioning was based on h44 of the 16S rRNA with the exception of nucleotides A1492 and A1493.](nihms223159f3){#F3}

###### 

Data collection and refinement statistics (molecular replacement)

                                 Viomycin                                                 Capreomycin
  ------------------------------ -------------------------------------------------------- -----------------------------------------------------
  **Data collection**                                                                     
  Space group                    P2~1~2~1~2~1~                                            P2~1~2~1~2~1~
  Cell dimensions                                                                         
      *a*, *b*, *c* (Å)          210.2, 448.5, 633.6                                      210.4, 448.2, 631.2
      α, β, γ (°)                90.0, 90.0, 90.0                                         90.0, 90.0, 90.0
  Resolution (Å)                 50 -- 3.25 (3.3-3.25) [\*](#TFN1){ref-type="table-fn"}   50.0-3.5 (3.6-3.5) [\*](#TFN1){ref-type="table-fn"}
  *R*~sym~ or *R*~merge~         32.9 (120.9)                                             19.8 (60.7)
  *I* / σ*I*                     4.2 (1.0)                                                5.6 (1.5)
  *I* / σ*I= 2*                  3.5                                                      3.6
  Completeness (%)               99.5 (98.9)                                              82.0 (54.3)
  Redundancy                     3.7 (2.0)                                                4.6 (2.8)
  **Refinement**                                                                          
  Resolution (Å)                 50 -- 3.15                                               50 -3.5
  No. reflections                1020688                                                  661327
  *R*~work~ / *R*~free~          24.8 / 27.2%                                             23.3 / 27.01%
  No. Atoms                                                                               
      rRNA                       189962                                                   189171
      r-protein                  93456                                                    93726
      tRNA/mRNA/antibiotic/ion   12158                                                    10879
  *B*-factors                    (Ask for input)                                          
      r-RNA                      83.2                                                     75.7
      r-protein                  89.8                                                     78.4
      Ligand/ion                 111.8                                                    114.1
  R.m.s. deviations                                                                       
      Bond lengths (Å)           0.008                                                    0.007
      Bond angles (°)            1.42                                                     1.27

Values in parentheses are for highest-resolution shell.
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